A clinical trial related to glucagon was registered on October 2, 2026. The study is titled "Hypothalamic GLP-1 Response in Healthy Weight and Obesity." Its current status is listed as not yet recruiting. The phase is listed as not applicable. The registration identifies the study under the number NCT07854886. No outcome data or results have been posted for this trial at this time. The listing indicates the study will examine hypothalamic GLP-1 response across participants of healthy weight and those with obesity, as reflected in the trial title. No further details about enrollment criteria, timeline, or design were included in the available record. This update reflects only the registration status as of the date provided and does not indicate that the trial has begun enrolling participants. Readers should treat this as an early stage notice rather than a report of findings. As the trial has not started recruiting, no conclusions about outcomes, safety, or efficacy can be drawn from this listing. For more background on this compound, readers can consult the compound overview for additional context.
Glucagon-Linked Trial on Hypothalamic GLP-1 Response Registered
See the full glucagon overview
Source: https://clinicaltrials.gov/study/NCT07854886